<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143581</url>
  </required_header>
  <id_info>
    <org_study_id>EMPATHY</org_study_id>
    <secondary_id>2019-004152-10</secondary_id>
    <nct_id>NCT04143581</nct_id>
  </id_info>
  <brief_title>SGLT2 Inhibitors in Glomerular Hyperfiltration</brief_title>
  <acronym>EMPATHY</acronym>
  <official_title>Evaluating the Short-Term Renal and Systemic Effects of SGLT2 Inhibition in Non-Diabetic Patients at Risk of Accelerated GFR Decline Because of Glomerular Hyperfiltration: a Sequential OFF-ON-OFF Study With One-Month Empagliflozin Therapy Followed by One-Month Recovery Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glomerular hyperfiltration is a major risk factor for accelerated glomerular filtration rate&#xD;
      (GFR) decline and renal and cardiovascular events despite optimized conservative therapy with&#xD;
      blood pressure and blood glucose (in diabetics) lowering medications and inhibitors of the&#xD;
      Renin Angiotensin System (RAS) such as Angiotensin Converting Enzyme (ACE) inhibitors and/or&#xD;
      Angiotensin Receptor Blockers (ARBs).&#xD;
&#xD;
      Progressive GFR decline initiated and sustained by glomerular hyperfiltration in subjects&#xD;
      with diabetes, unhealthy obesity, hypertension and other risk factors, is paralleled by&#xD;
      progressive glomerulosclerosis and loss of functioning nephrons.&#xD;
&#xD;
      The inhibition of the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubular segments&#xD;
      of the nephrons appears to be an ideal, specific intervention to inhibit the&#xD;
      tubulo-glomerular feedback and ameliorate glomerular hyperfiltration in subjects with&#xD;
      absolute or relative hyperfiltration associated with unhealthy obesity or proteinuric chronic&#xD;
      kidney disease (CKD). Indeed, by reducing tubular sodium reabsorption, SGLT2 inhibitors may&#xD;
      enhance sodium chloride delivery to the macula densa, restore pre-glomerular resistances and&#xD;
      therefore limit glomerular hyperperfusion and consequent hyperfiltration. Moreover, because&#xD;
      of its natriuretic effects, SGLT2 inhibition therapy might reduce the sodium overload and&#xD;
      volume expansion which, along with secondary hypertension, may further contribute to kidney&#xD;
      hyperperfusion and glomerular hyperfiltration in obesity and CKD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funds&#xD;
  </why_stopped>
  <start_date type="Actual">September 3, 2021</start_date>
  <completion_date type="Actual">September 3, 2021</completion_date>
  <primary_completion_date type="Actual">September 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>OFF/ON/OFF design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measured Glomerular Filtration Rate (GFR)</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>GFR will be measured by the iohexol plasma clearance technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary output</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>last of three consecutive collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary protein excretion</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>mean of the measurement in three consecutive 24-hour urine collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary albumin excretion</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>mean of the measurement in three consecutive 24-hour urine collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary urea excretion</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>last of three consecutive collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary phosphate excretion</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>last of three consecutive collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary sodium excretion</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>last of three consecutive collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary glucose excretion</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>last of three consecutive collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary potassium excretion</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>last of three consecutive collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary uric acid excretion</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>last of three consecutive collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary creatinine excretion</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>last of three consecutive collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional clearance of total protein calculated by standard formulas</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional clearance of albumin calculated by standard formulas</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional clearance of sodium calculated by standard formulas</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional clearance of potassium calculated by standard formulas</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional clearance of uric acid calculated by standard formulas</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional clearance of free water calculated by standard formulas</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose disposal rate</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>Performed by hyperinsulinemic euglycemic clamp and by standard oral glucose load and HOMA index;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>Performed by hyperinsulinemic euglycemic clamp and by standard oral glucose load and HOMA index;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office blood pressure</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office heart rate</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour (day-time and night-time) blood pressure monitoring</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour (day-time and night-time) heart rate monitoring</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>These parameters will be measured by tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other marker of vascular stiffness</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>These parameters will be measured by tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indices of Quality of Life: questionnaire SF-36</measure>
    <time_frame>Changes from baseline to the end of one-month treatment period and one-month recovery period</time_frame>
    <description>By submission of validate questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Obesity</condition>
  <condition>Non-diabetic Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>IMP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>Empagliflozin 10 mg/die for 28 days</description>
    <arm_group_label>IMP</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female â‰¥ 18 years old;&#xD;
&#xD;
          2. Increased risk of accelerated renal function loss because of absolute or relative&#xD;
             hyperfiltration associated with unhealthy obesity or residual proteinuria defined as:&#xD;
&#xD;
             Unhealthy obesity:&#xD;
&#xD;
               -  BMI &gt;30 kg/m^2 or waist circumference &gt;94 cm in males and &gt; 80 cm in females&#xD;
&#xD;
               -  Metabolic syndrome, defined as the presence of at least three of the following&#xD;
                  criteria:&#xD;
&#xD;
               -  Blood pressure&gt;140/90 mmHg or controlled blood pressure under current&#xD;
                  antihypertensive treatment&#xD;
&#xD;
               -  Triglyceride levels &gt;150 mg/dL&#xD;
&#xD;
               -  HDL&lt;40 mg/dL in males &lt;50 mg/dL in females&#xD;
&#xD;
               -  Fasting blood glucose &gt; 100 and &lt;125 mg/dL&#xD;
&#xD;
             Residual proteinuria:&#xD;
&#xD;
               -  Urinary protein excretion &gt;1g/24-h to &lt;3g/24-h despite RAS inhibitor therapy with&#xD;
                  ACE inhibitors or ARBs;&#xD;
&#xD;
               -  Blood pressure in recommended targets with or without blood pressure lowering&#xD;
                  medications;&#xD;
&#xD;
          3. Estimated GFR &gt; 60 ml/min/1.73m^2 (CKD-EPI formula);&#xD;
&#xD;
          4. Female childbearing potential and non-sterile male must agree to use a method of&#xD;
             contraception;&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1or 2 diabetic patients;&#xD;
&#xD;
          2. Concomitant treatment with insulin or oral hypoglycemic agents;&#xD;
&#xD;
          3. Nephrotic syndrome of any etiology;&#xD;
&#xD;
          4. Patients with Autosomal Dominant Polycystic Kidney Disease;&#xD;
&#xD;
          5. Symptomatic urinary tract lithiasis or obstruction;&#xD;
&#xD;
          6. Ischemic kidney disease (because of possible excess risk of acute kidney injury upon&#xD;
             SGLT2 inhibition associated reduction in sodium pool and kidney perfusion pressure);&#xD;
&#xD;
          7. Rapidly progressive kidney disease defined by impairment of renal function within 2&#xD;
             weeks - 3 months (for the cohort of patients with residual proteinuria only) ;&#xD;
&#xD;
          8. Active systemic autoimmune diseases;&#xD;
&#xD;
          9. Treatment for glomerulopathies or systemic diseases with steroids or any other&#xD;
             immunosuppressive agent within one year;&#xD;
&#xD;
         10. Specific contraindication to SGLT2 inhibitor therapy;&#xD;
&#xD;
         11. Heart failure with or without decreased systolic function;&#xD;
&#xD;
         12. Uncontrolled hypertension or symptomatic hypotension;&#xD;
&#xD;
         13. History of malignancy within 5 years of screening;&#xD;
&#xD;
         14. Inability to fully understand the possible risks and benefits related to study&#xD;
             participation;&#xD;
&#xD;
         15. If female, the subject is pregnant or lactating or intending to become pregnant&#xD;
             before, during, or within 90 days after last dose; or intending to donate ova during&#xD;
             such time period;&#xD;
&#xD;
         16. If male, the subject intends to donate sperm while on the study this study or for 90&#xD;
             days after last dose;&#xD;
&#xD;
         17. Alcohol and drug abuse;&#xD;
&#xD;
         18. Participation in another interventional clinical trial within the 4 weeks prior to&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GFR decline</keyword>
  <keyword>Glomerular hyperfiltration</keyword>
  <keyword>SGLT2 inhibitors</keyword>
  <keyword>Residual proteinuria</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

